CCIA
AMLX icon

Campbell & Co Investment Adviser’s Amylyx Pharmaceuticals AMLX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81M Buy
100,963
+46,541
+86% +$720K 0.1% 354
2026
Q1 		$756K Sell
54,422
-24,341
-31% -$342K 0.04% 602
2025
Q4 		$951K Buy
78,763
+54,281
+222% +$737K 0.05% 584
2025
Q3 		$333K Buy
+24,482
New +$230K 0.03% 878

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Campbell & Co Investment Adviser's AMLX Position: Q2 2026 in Review

Campbell & Co Investment Adviser increased its Amylyx Pharmaceuticals (AMLX) stake by 86% in Q2 2026, buying an estimated $720K and bringing the position to 100,963 shares worth $1.81M. The position accounts for 0.1% of the portfolio, ranked #354.

Campbell & Co Investment Adviser first reported a position in AMLX in Q3 2025 and has held it in 4 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Campbell & Co Investment Adviser held 100,963 shares of Amylyx Pharmaceuticals worth $1.81M as of Q2 2026.
  • Campbell & Co Investment Adviser bought 46,541 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $720K.
  • Amylyx Pharmaceuticals made up 0.1% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #354 holding.
  • Campbell & Co Investment Adviser first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.